# US Necrotising Enterocolitis Market > US Necrotizing Enterocolitis Market Research Report By End-User (Hospitals, Surgical and Ablation Centers, Research Institute, Others), By Treatment (Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Others), and By Distribution (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.01% - **2024:** $ 1,000 Million - **2025:** $ 1,060.1 Million - **2035:** $ 1,900 Million - **Key Players:** Abbott Laboratories (US), AptarGroup (US), Baxter International (US), Fresenius Kabi (DE), Medtronic (IE), Pediatric Nutrition (US), Reckitt Benckiser (GB), Nestle Health Science (CH) **Report ID:** MRFR/HC/53276-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** March 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-necrotising-enterocolitis-market-55040 --- ## Market Summary ## **US Necrotizing Enterocolitis Market Overview** As per MRFR analysis, the US Necrotizing Enterocolitis Market Size was estimated at 1.08 (USD Billion) in 2023. The US Necrotizing Enterocolitis Market is expected to grow from 1.2 (USD Billion) in 2024 to 2.3 (USD Billion) by 2035. The US Necrotizing Enterocolitis Market CAGR (growth rate) is expected to be around 6.093% during the forecast period (2025 - 2035). **Key US Necrotizing Enterocolitis Market Trends Highlighted** Healthcare advancements and growing awareness of neonatal health are driving major developments in the US necrotizing enterocolitis (NEC) market. The rising number of premature deliveries in the US, which increases the frequency of disorders like NEC in neonates, is one of the main factors propelling the market. Better outcomes for afflicted newborns are being supported by improved diagnosis and management techniques brought about by healthcare professionals' increased awareness of NEC. Better clinical practices focused on early detection and intervention are being brought about by increased cooperation between hospitals and pediatric healthcare providers. This is crucial for lowering the morbidity linked to NEC. The focus on research and development for novel treatment alternatives is another noteworthy trend. In order to prevent and manage NEC, there is a trend toward the development of novel therapeutics, such as pharmaceutical treatments and dietary changes. Clinical trials and educational programs aimed against NEC are increasing, indicating a dedication by healthcare organizations to investigate novel treatment approaches. The creation of preventative measures that include community health initiatives and parental education that emphasize breastfeeding, which has been proven to be effective in lowering the risk of NEC, is one opportunity to seize in the US market. Furthermore, using cutting-edge medical technology, like telemedicine, to continuously monitor at-risk newborns can increase patient care and management strategies' effectiveness. The US NEC market is poised for expansion, propelled by innovation and a cooperative approach among stakeholders committed to tackling this pressing health concern, with a particular emphasis on enhancing newborn healthcare outcomes. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review **US Necrotizing Enterocolitis Market Drivers** **Increasing Incidence of Necrotizing Enterocolitis** The rising incidence of Necrotizing Enterocolitis (NEC) among preterm infants is a significant driver for the US Necrotizing Enterocolitis Market. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 10 babies are born preterm in the United States, and those infants have a higher risk of developing NEC. As preterm birth rates continue to increase, driven in part by factors such as advanced maternal age and multiple births, hospitals and healthcare providers are increasingly compelled to invest in research, treatment options, and innovative solutions to prevent and manage NEC. Furthermore, the American Academy of Pediatrics emphasizes that with better neonatal care practices and improved survival rates of preterm infants, there is an anticipated increase in the overall number of NEC cases. This concerning trend creates a pressing demand for effective therapeutic strategies and underscores the growth potential within the US Necrotizing Enterocolitis Market. **Advancements in Treatment Protocols** Recent advancements in treatment protocols for Necrotizing Enterocolitis present a notable opportunity for growth within the US Necrotizing Enterocolitis Market. Innovations in surgical techniques, such as minimally invasive surgery, have shown promise in improving patient outcomes and reducing recovery times. Furthermore, ongoing Research and Development efforts by organizations like the National Institutes of Health (NIH) and private sector companies are fueling the development of new pharmaceuticals and biologicals aimed specifically at NEC. With increased funding and attention directed towards NEC treatment, it is projected that a more comprehensive array of treatment options will become available in the coming years, catering to the rising demand in the US and ultimately propelling market growth. **Growing Focus on Neonatal Health Initiatives** The growing focus on neonatal health initiatives in the United States is a key market driver for the US Necrotizing Enterocolitis Market. Health organizations such as the March of Dimes and the CDC are prioritizing neonatal care, which includes improving outcomes for preterm infants at risk for NEC. Legislative measures like the Newborn Screening Saves Lives Act have emphasized the importance of early detection and intervention for serious conditions, including NEC. As resources and funding are increasingly funneled into neonatal health programs, hospitals are more likely to adopt new diagnostic tools and treatment methods, further stimulating growth in the NEC market segment. This emphasis on enhancing neonatal care and reducing infant mortality rates is expected to drive demand for NEC-specific therapies in the coming years. **US Necrotizing Enterocolitis Market Segment Insights** **Necrotizing Enterocolitis Market End-User Insights** The End-User segment of the US Necrotizing Enterocolitis Market represents a crucial aspect of the overall healthcare landscape, particularly as it pertains to treating this severe gastrointestinal condition predominantly affecting premature infants. Hospitals generally account for a significant portion of this segment, as they provide comprehensive care facilities that encompass diagnostic, therapeutic, and surgical interventions. The presence of specialized neonatal units within hospitals facilitates immediate and effective management of necrotizing enterocolitis, making hospitals an indispensable component of the care continuum. Surgical and Ablation Centers also play a critical role, offering targeted procedural interventions for patients suffering from advanced forms of necrotizing enterocolitis. The surgical management of this condition can be complex and often involves collaboration between pediatric surgeons and neonatologists to ensure optimal outcomes. These centers specialize in performing intricate operations designed to remove necrotic bowel segments, thus contributing to improved patient recovery rates and long-term health. Research Institutes are increasingly becoming vital within this market, as they focus on advancing the understanding of necrotizing enterocolitis through clinical trials and innovative research. This segment is dedicated to exploring novel therapeutic approaches, enhancing diagnostic tools, and ultimately contributing to the body of knowledge necessary for better management practices. Ongoing studies in Research Institutes are critical for identifying potential risk factors and understanding the pathophysiology of the condition, which may lead to breakthroughs in prevention and treatment. In addition to these prominent categories, the "Others" segment encompasses a variety of non-traditional care settings that might include outpatient clinics, home care services, and educational organizations focused on necrotizing enterocolitis awareness. These entities contribute to the broader healthcare ecosystem by providing support services, follow-up care, and educational outreach to families coping with the implications of this condition. This segment provides alternative avenues for treatment and recovery, thereby ensuring that families have access to the most suitable care options. As the US healthcare system continues to evolve, various factors such as technological advancements, increasing awareness of early intervention, and an emphasis on specialized care are driving the growth of the End-User segment within the US Necrotizing Enterocolitis Market. The interplay between these various segments highlights the importance of a multidisciplinary approach to care, ensuring that patients receive comprehensive treatment tailored to their unique needs. As organizations and healthcare facilities collaborate more closely, the integration of services across hospitals, surgical centers, research institutions, and other healthcare setups will provide better outcomes for infants affected by necrotizing enterocolitis, ultimately benefiting the overall US healthcare landscape. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review **Necrotizing Enterocolitis Market Treatment Insights** The Treatment segment of the US Necrotizing Enterocolitis Market plays a crucial role in managing this serious condition predominantly affecting premature infants. With increased awareness and improved diagnostic techniques, the market has evolved to incorporate various methods, such as Total Parenteral Nutrition, which is vital for providing nutrition to infants with compromised gastrointestinal function. Gastrointestinal Decompression is also significant as it helps relieve distension and restores functional bowel viability. Antimicrobial Therapy is essential in combating infections, while Antifungal Treatment addresses the prevalent risks posed by fungal pathogens in these vulnerable patients. Paracentesis serves as a helpful intervention for managing fluid accumulation, contributing to patient comfort and recovery. Market growth is driven by rising incidences of necrotizing enterocolitis, alongside advancements in treatment technologies and protocols, enhancing survival rates. Despite challenges, such as varying regional healthcare access and treatment costs, the overall outlook for the Treatment segment remains positive, thanks to ongoing Research and Development initiatives aimed at improving patient outcomes. As a result, key treatment methods continue to dominate discussions in the medical community, fostering further innovation within the US Necrotizing Enterocolitis Market. **Necrotizing Enterocolitis Market Distribution Insights** The Distribution segment of the US Necrotizing Enterocolitis Market plays a crucial role in ensuring accessibility and availability of therapeutic products to healthcare providers and patients. The segment encompasses various channels including Direct Tender, Hospital Pharmacy, [Retail Pharmacy](../../../reports/retail-pharmacy-market-22432), Online Pharmacy, and others, each contributing uniquely to the market dynamics. Hospital Pharmacies are essential as they facilitate immediate access to medications for inpatients, reflecting the urgency and critical care required for necrotizing enterocolitis cases. On the other hand, Online Pharmacies are gaining prominence due to the increasing trend of telemedicine and digital health solutions, offering convenience and efficient service for patients seeking medications. Retail Pharmacies also maintain significant market influence, providing direct access to caregivers and families, thus enhancing patient adherence to treatment. Meanwhile, Direct Tender arrangements are vital for securing bulk purchases and ensuring that essential drugs reach hospitals and clinics effectively. Each of these distribution channels not only caters to the diverse needs of healthcare providers but also addresses the varied accessibility requirements of patients across the United States, driving overall growth and efficiency in the US Necrotizing Enterocolitis Market. Increasing awareness about the condition and the rising incidence rates are expected to further propel the importance of these distribution avenues in the upcoming years. **US Necrotizing Enterocolitis Market Key Players and Competitive Insights** The competitive insights of the US Necrotizing Enterocolitis Market reveal a dynamic landscape characterized by diverse stakeholders who are striving to enhance patient care and treatment outcomes. This segment primarily focuses on addressing the medical needs surrounding necrotizing enterocolitis, a serious intestinal condition primarily affecting premature infants. The market is driven by increasing awareness of the condition, advancements in medical technology, and the growing demand for innovative treatment solutions. Stakeholders in the market include various players from pharmaceutical companies to medical device manufacturers, each vying for a significant foothold in this specialized arena. The essence of competition revolves around the development of effective therapies, improving diagnostic methods, and establishing strategic partnerships to expand market reach and improve patient outcomes. In the context of the US Necrotizing Enterocolitis Market, Hollister has established a strong presence marked by its commitment to innovative product development and patient-centered solutions. The company's expertise in medical devices and ostomy care has allowed it to cater to the specific needs of this niche market effectively. Hollister's strengths lie in its robust research and development pipeline, which enables it to deliver high-quality products tailored for neonatal care. Additionally, the company benefits from a reputation for reliability and clinical efficacy, making its offerings preferred among healthcare professionals dealing with necrotizing enterocolitis. Through educational initiatives and clinical partnerships, Hollister aims to educate healthcare providers and caregivers about optimal care practices, further solidifying its position in the market. Medtronic, a prominent player in the US medical technology landscape, boasts a comprehensive portfolio of products and services pertinent to the Necrotizing Enterocolitis Market. The company is well-regarded for its extensive range of medical devices that enhance surgical procedures and patient monitoring in neonatal care. Medtronic's strengths are underscored by its continuous investment in research and development, which leads to pioneering solutions aimed at improving surgical outcomes for infants suffering from this condition. The company's presence in the market is bolstered by strategic mergers and acquisitions that expand its capabilities and product offerings. Medtronic has formed collaborative relationships with healthcare institutions to facilitate clinical studies, reinforcing its role as a leader in this domain. Their combination of advanced technology, experience, and commitment to improving care pathways for vulnerable patients position Medtronic as a crucial competitor in the US Necrotizing Enterocolitis Market. **Key Companies in the US Necrotizing Enterocolitis Market Include** - Hollister - Medtronic - Acelity - Purdue Pharma - Danone - Baxter - Chiesi Farmaceutici - Janssen Pharmaceuticals - MediTouch - PediaMed Pharmaceuticals - Nestle - AbbVie - Elekta - Jude Medical - Sakraida Medical **US Necrotizing Enterocolitis Market Developments** Recent developments in the US Necrotizing Enterocolitis Market focus on the increasing awareness and prevalence of this serious gastrointestinal condition affecting premature infants. Companies such as Medtronic and Baxter are innovating with advanced medical devices and therapies aimed at early diagnosis and treatment. In terms of market valuation growth, investments in R&D by firms like Acelity and AbbVie have led to advancements in cell and gene therapies, contributing to a more favorable treatment landscape. The market also saw significant activity in mergers and acquisitions; for instance, in July 2023, Hollister made headlines with its acquisition of a smaller firm focused on innovative neonatal care solutions, aiming to enhance its product portfolio. Another notable event occurred in August 2023 when Danone announced its strategic partnership with a biotech firm to develop a new nutritional formula specifically targeting neonates at risk of Necrotizing Enterocolitis. These trends reflect a concerted effort across major healthcare players to address a critical need within neonatal care while leveraging the latest technologies and therapies to improve outcomes for vulnerable patients. **Necrotizing Enterocolitis Market Segmentation Insights** - **Necrotizing Enterocolitis Market End-User Outlook** - Hospitals - Surgical and Ablation Centers - Research Institute - Others - **Necrotizing Enterocolitis Market Treatment Outlook** - Total Parenteral Nutrition (TPN) - Gastrointestinal Decompression - Antimicrobial Therapy - Antifungal Treatment - Paracentesis - Others - **Necrotizing Enterocolitis Market Distribution Outlook** - Direct Tender - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy - Others ## Market Drivers ### Rising Healthcare Expenditure The upward trend in healthcare expenditure in the US is a significant driver for the [necrotising enterocolitis](https://www.marketresearchfuture.com/reports/necrotising-enterocolitis-market-5999) market. With healthcare spending projected to reach approximately $4.1 trillion by 2025, there is a growing focus on improving neonatal care and addressing conditions like necrotising enterocolitis. Increased funding for research and development in this area is likely to lead to the introduction of novel therapies and treatment protocols. Additionally, as healthcare systems prioritize preventive measures and early interventions, the demand for effective solutions in managing necrotising enterocolitis is expected to rise, thereby positively impacting market dynamics. ### Growing Focus on Preventive Healthcare The growing emphasis on preventive healthcare measures is influencing the necrotising enterocolitis market. Healthcare providers are increasingly adopting strategies aimed at reducing the incidence of this condition through better prenatal care and nutritional support for at-risk infants. Initiatives promoting breastfeeding and the use of probiotics are gaining traction, as they are believed to lower the risk of necrotising enterocolitis. This shift towards prevention is likely to drive demand for related products and services, thereby impacting market growth. As awareness of preventive measures continues to rise, the necrotising enterocolitis market may experience a corresponding increase in investment and innovation. ### Technological Innovations in Medical Devices Technological advancements in medical devices play a pivotal role in shaping the necrotising enterocolitis market. Innovations such as improved imaging techniques and monitoring systems enhance the early detection and management of the condition. For instance, the integration of artificial intelligence in diagnostic tools may lead to more accurate assessments, thereby improving patient outcomes. The market for medical devices related to necrotising enterocolitis is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of around 8-10 % over the next few years. This growth is driven by the increasing adoption of advanced technologies in neonatal care. ### Enhanced Research and Development Initiatives The emphasis on research and development initiatives in the field of neonatology is a crucial driver for the necrotising enterocolitis market. Increased funding from both public and private sectors is facilitating the exploration of new treatment modalities and preventive strategies. Collaborative efforts among academic institutions, healthcare providers, and pharmaceutical companies are likely to yield innovative solutions for managing necrotising enterocolitis. The market is expected to benefit from breakthroughs in understanding the pathophysiology of the condition, which may lead to targeted therapies. This focus on R&D is anticipated to foster a more robust pipeline of products aimed at addressing the needs of affected infants. ### Increasing Incidence of Necrotising Enterocolitis The rising incidence of necrotising enterocolitis among premature infants is a critical driver for the necrotising enterocolitis market. Studies indicate that the condition affects approximately 7-10 % of infants born before 32 weeks of gestation. This increasing prevalence necessitates enhanced medical interventions and treatment options, thereby propelling market growth. As healthcare providers become more vigilant in diagnosing and managing this condition, the demand for specialized products and therapies is likely to rise. Furthermore, the growing number of neonatal intensive care units (NICUs) across the US is expected to contribute to the increased detection and treatment of necrotising enterocolitis, further stimulating market expansion. ## Future Outlook It is projected to grow at 6.01% CAGR from 2025 to 2035., driven by advancements in neonatal care and increased awareness. **New opportunities:** - Development of targeted therapies for high-risk infants - Expansion of telehealth services for remote monitoring - Investment in advanced diagnostic technologies for early detection By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and increased healthcare investments. ## Segment Insights ### By End-User: Hospitals (Largest) vs. Surgical and Ablation Centers (Fastest-Growing) The distribution of the US necrotising enterocolitis market among end-user segments highlights a significant presence of hospitals, which account for the largest share. This dominance is primarily due to their extensive resources and capacity to provide comprehensive patient care. Surgical and ablation centers also play a crucial role in this market, capturing a noteworthy share and demonstrating their importance in specialized treatments for necrotising enterocolitis. Growth trends in the end-user segment indicate a robust increase in the reliance on surgical and ablation centers, which are emerging as the fastest-growing segment. The need for advanced surgical interventions and specialized care in these facilities is being driven by rising incidences of the condition and greater awareness of available treatment options. Additionally, hospitals continue to innovate and expand their capabilities, allowing them to maintain their dominant position while adapting to changing healthcare demands. Hospitals (Dominant) vs. Surgical and Ablation Centers (Emerging) In the US necrotising enterocolitis market, hospitals are recognized as the dominant end-user segment due to their comprehensive healthcare services and infrastructure. They provide critical care and advanced treatment options, attracting a large patient population. Conversely, surgical and ablation centers represent an emerging market segment, specializing in targeted surgical interventions for necrotising enterocolitis, which contribute to their rapid growth. The increasing adoption of minimally invasive surgical techniques and improved patient outcomes are enhancing their appeal. Both segments are essential to the overall market, yet they cater to different patient needs and treatment protocols, ensuring a diverse approach to managing this serious condition. ### By Treatment: Total Parenteral Nutrition (Largest) vs. Gastrointestinal Decompression (Fastest-Growing) In the US necrotising enterocolitis market, Total [Parenteral Nutrition](https://www.marketresearchfuture.com/reports/parenteral-nutrition-market-43392) (TPN) holds the largest share among treatment options, reflecting its critical role in managing severe conditions. Gastrointestinal Decompression is recognized as the fastest-growing treatment segment due to its effectiveness in relieving intestinal obstruction, thereby enhancing overall patient outcomes. Other treatment options like Antimicrobial Therapy and Antifungal Treatment also contribute to market dynamics but do not match the prominence of TPN and the growth trajectory of Gastrointestinal Decompression. Over recent years, the trend towards minimally invasive techniques has favored Gastrointestinal Decompression, leading to its rapid adoption in clinical settings. The increasing prevalence of necrotising enterocolitis among premature infants has driven demand for effective treatment methods. Advances in medical technology and growing awareness among healthcare providers regarding treatment efficacy are expected to further propel the growth of both TPN and Gastrointestinal Decompression, ensuring these methods remain central to management strategies. Total Parenteral Nutrition (Dominant) vs. Gastrointestinal Decompression (Emerging) Total Parenteral Nutrition (TPN) is established as a dominant force within the treatment landscape for necrotising enterocolitis, primarily due to its ability to provide essential nutrients directly into the bloodstream, bypassing the gastrointestinal tract. This treatment is critical for patients with severe conditions, where traditional feeding routes are compromised. Conversely, Gastrointestinal Decompression is emerging as a vital technique that addresses intestinal blockages efficiently, thereby reducing complications associated with necrotising enterocolitis. The increasing preference for less invasive methods is promoting Gastrointestinal Decompression, positioning it as a significant part of future treatment protocols. Both treatment options are crucial to improving patient outcomes and are shaping the evolving landscape of the US necrotising enterocolitis market. ### By Distribution: Direct Tender (Largest) vs. Online Pharmacy (Fastest-Growing) The distribution of the US necrotising enterocolitis market showcases a diverse landscape among various segments. Direct Tender holds the largest share, driven by traditional procurement methods used in hospitals and healthcare facilities. In contrast, Online Pharmacy is emerging with a rapidly growing presence, appealing to a tech-savvy demographic seeking convenience and quick access to medications. Growth trends indicate a shift towards greater online sales and pharmaceutical services. The rising adoption of e-commerce in healthcare is a key factor for Online Pharmacy, while Direct Tender remains robust due to established procurement practices in the medical field. The demand for efficient and accessible treatment options drives the evolution of distribution channels, highlighting a blend of traditional and innovative approaches in the market. Direct Tender (Dominant) vs. Online Pharmacy (Emerging) Direct Tender is recognized as the dominant player in the distribution segment, primarily utilized by healthcare institutions for bulk procurement. This model ensures reliability and cost-effectiveness in delivering medications for the treatment of necrotising enterocolitis. Its established structure supports strong supplier relationships and negotiation power, appealing to hospitals that prioritize consistent supply. Conversely, Online Pharmacy represents the emerging segment, rapidly gaining traction among consumers who prefer the convenience of online shopping. This trend is accelerated by increased smartphone usage and a growing acceptance of telemedicine. Online Pharmacies provide an alternative channel for accessing critical treatments, appealing to a new generation of patients, thus strategically complementing the traditional distribution methods in the overall market. ## Competitive Benchmarking The necrotising enterocolitis market is characterized by a dynamic competitive landscape, driven by increasing awareness of neonatal health and advancements in medical technology. Key players such as Abbott Laboratories (US), Baxter International (US), and Nestle Health Science (CH) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Abbott Laboratories (US) focuses on developing specialized nutritional products aimed at preterm infants, while Baxter International (US) emphasizes its commitment to supply chain optimization and local manufacturing to ensure product availability. Nestle Health Science (CH) is actively pursuing collaborations with healthcare providers to improve nutritional interventions, thereby shaping a competitive environment that prioritizes quality and accessibility.The market structure appears moderately fragmented, with several players vying for market share through various business tactics. Localizing manufacturing and optimizing supply chains are critical strategies employed by these companies to enhance operational efficiency and reduce costs. The collective influence of these key players fosters a competitive atmosphere where innovation and responsiveness to market needs are paramount. In October Abbott Laboratories (US) announced the launch of a new line of infant formula specifically designed to support gut health in premature infants. This strategic move is significant as it aligns with the growing demand for specialized nutritional products that cater to vulnerable populations, potentially enhancing Abbott's market share and reinforcing its reputation as a leader in neonatal nutrition. In September Baxter International (US) expanded its product portfolio by acquiring a small biotech firm specializing in advanced therapies for neonatal conditions. This acquisition is likely to bolster Baxter's capabilities in developing innovative solutions for necrotising enterocolitis, positioning the company to better address the complexities of this condition and meet the evolving needs of healthcare providers. In August Nestle Health Science (CH) entered into a partnership with a leading pediatric hospital to conduct clinical trials on a new nutritional supplement aimed at reducing the incidence of necrotising enterocolitis. This collaboration underscores Nestle's commitment to evidence-based solutions and may enhance its credibility in the market, while also providing valuable insights into the effectiveness of its products. As of November current trends in the necrotising enterocolitis market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in product development and patient care. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, reflecting a broader industry trend towards enhancing patient outcomes and operational excellence. ## Recent News & Developments Recent developments in the US Necrotizing Enterocolitis Market focus on the increasing awareness and prevalence of this serious gastrointestinal condition affecting premature infants. Companies such as Medtronic and Baxter are innovating with advanced medical devices and therapies aimed at early diagnosis and treatment. In terms of market valuation growth, investments in R&D by firms like Acelity and AbbVie have led to advancements in cell and gene therapies, contributing to a more favorable treatment landscape. The market also saw significant activity in mergers and acquisitions; for instance, in July 2023, Hollister made headlines with its acquisition of a smaller firm focused on innovative neonatal care solutions, aiming to enhance its product portfolio. Another notable event occurred in August 2023 when Danone announced its strategic partnership with a biotech firm to develop a new nutritional formula specifically targeting neonates at risk of Necrotizing Enterocolitis. These trends reflect a concerted effort across major healthcare players to address a critical need within neonatal care while leveraging the latest technologies and therapies to improve outcomes for vulnerable patients. ## Report Scope | MARKET SIZE 2024 | 1000.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1060.1(USD Million) | | MARKET SIZE 2035 | 1900.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.01% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), AptarGroup (US), Baxter International (US), Fresenius Kabi (DE), Medtronic (IE), Pediatric Nutrition (US), Reckitt Benckiser (GB), Nestle Health Science (CH) | | Segments Covered | End-User, Treatment, Distribution | | Key Market Opportunities | Advancements in neonatal care technologies enhance treatment options in the necrotising enterocolitis market. | | Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the necrotising enterocolitis market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US necrotising enterocolitis market in 2024?** A: The market valuation was $1000.0 Million in 2024. **Q: What is the projected market valuation for the US necrotising enterocolitis market by 2035?** A: The projected valuation for 2035 is $1900.0 Million. **Q: What is the expected CAGR for the US necrotising enterocolitis market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.01%. **Q: Which companies are considered key players in the US necrotising enterocolitis market?** A: Key players include Abbott Laboratories, AptarGroup, Baxter International, and others. **Q: What are the primary end-user segments in the US necrotising enterocolitis market?** A: Primary end-user segments include Hospitals, Surgical and Ablation Centers, and Research Institutes. **Q: What was the market size for Hospitals in the US necrotising enterocolitis market in 2024?** A: The market size for Hospitals was $400.0 Million to $760.0 Million in 2024. **Q: What treatment segments are included in the US necrotising enterocolitis market?** A: Treatment segments include Total Parenteral Nutrition, Antimicrobial Therapy, and Gastrointestinal Decompression. **Q: What was the market size for Antimicrobial Therapy in 2024?** A: The market size for Antimicrobial Therapy ranged from $300.0 Million to $570.0 Million in 2024. **Q: How is the distribution of products managed in the US necrotising enterocolitis market?** A: Distribution is managed through Direct Tender, Hospital Pharmacy, and Online Pharmacy. **Q: What was the market size for Online Pharmacy in 2024?** A: The market size for Online Pharmacy was between $250.0 Million and $475.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-necrotising-enterocolitis-market-55040*